Report
Patrik Ling
EUR 95.03 For Business Accounts Only

Targovax (Buy, TP: NOK17.00) - Strong data in melanoma

Targovax reported strong data in its melanoma trial. In this trial, patients’ refractory to CPI therapy was treated with ONCOS-102 in combination with pembrolizumab for up to 24 weeks. The overall data (20 patients from part 1 and part 2) showed a c35% ORR. We believe that this is good data and should support the company moving forward in this indication. On the conference call on 2 December, the company stated it that will take some time to design and initiate the next trial and that it is doubtful such a trial can start during 2021. We regard the share price reaction following the data – up close to c30% – as reasonable.
Underlying
Targovax AS

Targovax ASA is a Norway-based company active within the healthcare sector. The Company is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company's candidate, TG01, is a peptide vaccine that targets mutations in the RAS genes that are associated with cancer, and it is in a phase II clinical trial in pancreatic cancer. The Company's other RAS targeting immunotherapy, TG02 is developed for colorectal cancer treatment. The Company's adenoviral candidate, ONCOS-102 is developed for the treatment of solid tumors, such as melanoma as well as ovarian and prostate cancer.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Patrik Ling

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch